Develops and manufactures life sciences tools and quality control products. Offers sterilization and disinfection control solutions for healthcare facilities. Now — the numbers.
Revenue is spread across several lines; no single product carries the company.
This is an established company with proven profits.
The gap is $141.9M. In times of high interest rates, a gap like that can squeeze a company.
The market pays 100.8× for every dollar this company earns in a year — a price that already assumes things go well.
Against companies in its own sector, it looks cheaper than 67% of them.
Analysts' average target sits 9% below today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
This grade is a blend: the profit side is strong, the sales tempo slow.
The stock has been running stronger than the market lately.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
An investor who bought at the very peak is down 64% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 12 months, company executives reported 29 buys and 24 sells. Management buying with its own money is usually read as a good sign.
It pays out $0.64 per share each year — regular cash for whoever holds the stock.
The company’s market value is 101 times its annual profit. Even a small disappointment could hit the price hard.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 49/100.
On our five-subject report card, MLAB sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: MLAB does earn real profits — but on our report card it still sits behind its class. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.